Nanotechnology for Delivery of Drugs to the Brain for Epilepsy

Neurotherapeutics

Volumn 6, Issue 2, 2009, Pages 323-336

  Bennewitz, Margaret F ^a   Saltzman, W Mark ^a  

^a Yale University   (United States)

Author keywords

antiepileptic drugs; blood brain barrier; CNS delivery; drug delivery systems; Epilepsy; seizures

Indexed keywords

ANTICONVULSIVE AGENT; FOSPHENYTOIN SODIUM; GABAPENTIN; GABAPENTIN ENACARBIL; LIDOCAINE; LIPOSOME; MACROGOL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY OX26; MRZ 2 576; MUSCIMOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NANOPARTICLE; OMEGA CONOTOXIN CVID; OMEGA CONOTOXIN MVIIA; PHENOBARBITAL; PHENYTOIN; POLYCAPROLACTONE; POLYGLACTIN; POLYGLYCOLIC ACID; POLYLACTIC ACID; POLYMER; POLYSACCHARIDE; PROBENECID; PRODRUG; PROGESTERONE; TIAGABINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL;

ABSENCE; ANTICONVULSANT ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; EPILEPSY; EPILEPTIC STATE; HUMAN; LIPOSOMAL DELIVERY; NANOTECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; SEIZURE; TONIC CLONIC SEIZURE;

ANIMALS; ANTICONVULSANTS; BLOOD-BRAIN BARRIER; DRUG DELIVERY SYSTEMS; EPILEPSY; HUMANS; NANOTECHNOLOGY;

EID: 62949089810     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2009.01.018     Document Type: Article

References (116)

1. De Tiège X., Laufs H., Boyd S.G., et al. EEG-fMRI in children with pharmacoresistant focal epilepsy. Epilepsia 48 (2007) 385-389
2. Pardridge W.M. Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv 3 (2003) 90-105 51
3. Barnett G.H. High-grade gliomas: diagnosis and treatment (2006), Humana Press, Totowa, NJ
4. Abbott N.J., Rönnbäck L., and Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7 (2006) 41-53
5. Fisher R.S., and Ho J. Potential new methods for antiepileptic drug delivery. CNS Drugs 16 (2002) 579-593
6. Müller R.H. Colloidal carriers for controlled drug delivery and targeting: modification, characterization, and in vivo distribution (1991), CRC Press, Boca Raton, FL
7. Yang S.C., Lu L.F., Cai Y., Zhu J.B., Liang B.W., and Yang C.Z. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release 59 (1999) 299-307
8. Muller R.H., Petersen R.D., Hommoss A., and Pardeike J. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev 59 (2007) 522-530
9. Saad M., Garbuzenko O.B., Ber E., et al. Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging?. J Control Release 130 (2008) 107-114
10. Klingeler R., Hampel S., and Büchner B. Carbon nanotube based biomedical agents for heating, temperature sensing and drug delivery. Int J Hyperthermia 24 (2008) 496-505
11. Couvreur P., and Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm Res 23 (2006) 1417-1450
12. Barratt G.M. Therapeutic applications of colloidal drug carriers. Pharm Sci Technolo Today 3 (2000) 163-171
13. Sharma A., and Sharma U.S. Liposomes in drug delivery: progress and limitations. Int J Pharm 154 (1997) 123-140
14. Dutt M., and Khuller G.K. Liposomes and PLG microparticles as sustained release antitubercular drug carriers: an in vitro-in vivo study. Int J Antimicrob Agents 18 (2001) 245-252
15. Verdun C., Brasseur F., Vranckx H., Couvreur P., and Roland M. Tissue distribution of doxorubicin associated with polyisohexylcyanoacrylate nanoparticles. Cancer Chemother Pharmacol 26 (1990) 13-18
16. Date A.A., Joshi M.D., and Patravale V.B. Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv Drug Deliv Rev 59 (2007) 505-521
17. Thorne R.G., and Nicholson C. In vivo diffusion analysis with quantum dots and dextrans predicts the width of brain extracellular space. Proc Natl Acad Sci U S A 103 (2006) 5567-5572
18. Birnbaum D.T., Kosmala J.D., and Brannon-Peppas L. Optimization of preparation techniques for poly(lactic acid-co-glycolic acid) nanoparticles. J Nanoparticle Res 2 (2000) 173-181
19. Ito F., Fujimori H., and Makino K. Incorporation of water-soluble drugs in PLGA microspheres. Colloids Surf B Biointerfaces 54 (2007) 173-178
20. MacKay J., Deen D.F., and Szoka Jr. F.C. Distribution in brain of liposomes after convection enhanced delivery: modulation by particle charge, particle diameter, and presence of steric coating. Brain Res 1035 (2005) 139-153
21. Jain R.A. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21 (2000) 2475-2490
22. Lockman P.R., Mumper R.J., Khan M.A., and Allen D.D. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm 28 (2002) 1-13
23. Yasukawa T., Ogura Y., Sakurai E., Tabata Y., and Kimura H. Intraocular sustained drug delivery using implantable polymeric devices. Adv Drug Deliv Rev 57 (2005) 2033-2046
24. Paasonen L., Romberg B., Storm G., Yliperttula M., Urtti A., and Hennink W.E. Temperature-sensitive poly(N-(2-hydroxypropyl)methacrylamide mono/dilactate)-coated liposomes for triggered contents release. Bioconjug Chem 18 (2007) 2131-2136
25. Drummond D.C., Zignani M., and Leroux J. Current status of pH-sensitive liposomes in drug delivery. Prog Lipid Res 39 (2000) 409-460
26. Alexis F., Pridgen E., Molnar L.K., and Farokhzad O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5 (2008) 505-515
27. Van Vlerken L.E., Vyas T.K., and Amiji M.M. Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm Res 24 (2007) 1405-1414
28. Peracchia M.T., Fattal E., Desmaële D., et al. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J Control Release 60 (1999) 121-128
29. Panagi Z., Beletsi A., Evangelatos G., Livaniou E., Ithakissios D.S., and Avgoustakis K. Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. Int J Pharm 221 (2001) 143-152
30. Gabizon A., Shmeeda H., and Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 42 (2003) 419-436
31. 99mTc-HMPAO-liposome for improving blood circulation and biodistribution: the effect of the extent of PEGylation. Cancer Biother Radiopharm 20 (2005) 620-628
32. Jeon S.I., Lee J.H., Andrade J.D., and De Gennes P.G. Protein-surface interactions in the presence of polyethylene oxide: I. Simplified theory. J Colloid Interface Sci 142 (1991) 149-158
33. Owens III D.E., and Peppas N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 307 (2006) 93-102
34. Rapoport S. Modulation of blood-brain barrier permeability. J Drug Target 3 (1996) 417-425
35. Béduneau A., Saulnier P., and Benoit J.P. Active targeting of brain tumors using nanocarriers. Biomaterials 28 (2007) 4947-4967
36. Schnyder A., and Huwyler J. Drug transport to brain with targeted liposomes. NeuroRx 2 (2005) 99-107
37. Umezawa F., and Eto Y. Liposome targeting to mouse brain: mannose as a recognition marker. Biochem Biophys Res Commun 153 (1988) 1038-1044
38. Mora M., Sagristá M.L., Trombetta D., Bonina F.P., De Pasquale A., and Saija A. Design and characterization of liposomes containing long-chain N-acylPEs for brain delivery: penetration of liposomes incorporating GM1 into the rat brain. Pharm Res 19 (2002) 1430-1438
39. Fenart L., Casanova A., Dehouck B., et al. Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross and in vitro model of the blood-brain barrier. J Pharmacol Exp Ther 291 (1999) 1017-1022
40. Allen D.D., and Lockman P.R. The blood-brain barrier choline transporter as a brain drug delivery vector. Life Sci 73 (2003) 1609-1615
41. Friese A., Seiller E., Quack G., Lorenz B., and Kreuter J. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur J Pharm Biopharm 49 (2000) 103-109
42. Kreuter J., Shamenkov D., Petrov V., et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target 10 (2002) 317-325
43. Olivier J.C. Drug transport to brain with targeted nanoparticles. NeuroRx 2 (2005) 108-119
44. Aktaş Y., Yemisci M., Andrieux K., et al. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjug Chem 16 (2005) 1503-1511
45. Huwyler J., Wu D., and Pardridge W.M. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci U S A 93 (1996) 14164-14169
46. Schnyder A., Krähenbühl S., Drewe J., and Huwyler J. Targeting of daunomycin using biotinylated immunoliposomes: pharmacokinetics, tissue distribution and in vitro pharmacological effects. J Drug Target 13 (2005) 325-335
47. Huwyler J., Yang J., and Pardridge W.M. Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat. J Pharmacol Exp Ther 282 (1997) 1541-1546
48. Cerletti A., Drewe J., Fricker G., Eberle A.N., and Huwyler J. Endocytosis and transcytosis of an immunoliposome-based brain drug delivery system. J Drug Target 8 (2000) 435-446
49. Kelly K. Gabapentin: antiepileptic mechanism of action. Neuropsychobiology 38 (1998) 139-144
50. Trojnar M.K., Wierzchowska-Cioch E., Krzyzanowski M., Jargiełło M., and Czuczwar S.J. New generation of valproic acid. Pol J Pharmacol 56 (2004) 283-288
51. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Loiseau P., and Perucca E. Progress report on new antiepileptic drugs: a summary of the fifth Eilat conference (EILAT V). Epilepsy Res 43 (2001) 11-58
52. Rautio J., Kumpulainen H., Heimbach T., et al. Prodrugs: design and clinical applications [Erratum in: Nat Rev Drug Discov 2008;7:272]. Nat Rev Drug Discov 7 (2008) 255-270
53. Fechner J., Schwilden H., and Schüttler J. Pharmacokinetics and pharmacodynamics of GPI 15715 or fospropofol (Aquavan injection): a water-soluble propofol prodrug. Handb Exp Pharmacol 182 (2008) 253-266
54. Knapp L.E., and Kugler A.R. Clinical experience with fosphenytoin in adults: pharmacokinetics, safety, and efficacy. J Child Neurol 13 Suppl 1 (1998) S15-S18 discussion S30-S32
55. Cundy K.C., Branch R., Chernov-Rogan T., et al. XP13512 [(±)-1-([(α-Isobutanoyloxyethoxy)carbonyl]aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther 311 (2004) 315-323
56. Cundy K.C., Annamalai T., Bu L., et al. XP13512 [(±)-1-([(α-Isobutanoyloxyethoxy)carbonyl]aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther 311 (2004) 324-333
57. Löscher W., and Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2 (2005) 86-98
58. Tishler D.M., Weinberg K.I., Hinton D.R., Barbaro N., Annett G.M., and Raffel C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 36 (1995) 1-6
59. Potschka H., Fedrowitz M., and Löscher W. Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J Pharmacol Exp Ther 306 (2003) 124-131
60. Aronica E., Gorter J.A., Jansen G.H., et al. Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: focal cortical dysplasia and glioneuronal tumors. Neuroscience 118 (2003) 417-429
61. Sisodiya S.M., Lin W.R., Squier M.V., and Thom M. Multidrug-resistance protein 1 in focal cortical dysplasia. Lancet 357 (2001) 42-43
62. Dombrowski S.M., Desai S.Y., Marroni M., et al. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 42 (2001) 1501-1506
63. Lazarowski A., Ramos A.J., García-Rivello H., Brusco A., and Girardi E. Neuronal and glial expression of the multidrug resistance gene product in an experimental epilepsy model. Cell Mol Neurobiol 24 (2004) 77-85
64. Chengyun D., Guoming L., Elia M., Catania M., and Qunyuan X. Expression of multidrug resistance type 1 gene (MDR1) P-glycoprotein in intractable epilepsy with different aetiologies: a double-labelling and electron microscopy study. Neurol Sci 27 (2006) 245-251
65. Aronica E., Gorter J.A., Ramkema M., et al. Expression and cellular distribution of multidrug resistance-related proteins in the hippocampus of patients with mesial temporal lobe epilepsy. Epilepsia 45 (2004) 441-451
66. Sisodiya S.M., Martinian L., Scheffer G.L., et al. Vascular colocalization of P-glycoprotein, multidrug-resistance associated protein 1, breast cancer resistance protein, and major vault protein in human epileptogenic pathologies. Neuropathol Appl Neurobiol 32 (2006) 51-63
67. Vogelgesang S., Kunert-Keil C., Cascorbi I., et al. Expression of multidrug transporters in dysembryoplastic neuroepithelial tumors causing intractable epilepsy. Clin Neuropathol 23 (2004) 223-231
68. Summers M.A., Moore J.L., and McAuley J.W. Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. Ann Pharmacother 38 (2004) 1631-1634
69. Iannetti P., Spalice A., and Parisi P. Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus. Epilepsia 46 (2005) 967-969
70. Brandt C., Bethmann K., Gastens A.M., and Löscher W. The multidrug transporter hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy. Neurobiol Dis 24 (2006) 202-211
71. Thomas H., and Coley H.M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 10 (2003) 159-165
72. Van Vliet E.A., Redeker S., Aronica E., Edelbroek P.M., and Gorter J.A. Expression of multidrug transporters MRP1, MRP2, and BCRP shortly after status epilepticus, during the latent period, and in chronic epileptic rats. Epilepsia 46 (2005) 1569-1580
73. Baltes S., Gastens A.M., Fedrowitz M., Potschka H., Kaever V., and Löscher W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology 52 (2007) 333-346
74. Cerveny L., Pavek P., Malakova J., Staud F., and Fendrich Z. Lack of interactions between breast cancer resistance protein (BCRP/ABCG2) and selected antiepileptic agents. Epilepsia 47 (2006) 461-468
75. Haluska M., and Anthony M.L. Osmotic blood-brain barrier modification for the treatment of malignant brain tumors. Clin J Oncol Nurs 8 (2004) 263-267
76. Siegal T., Rubinstein R., Bokstein F., et al. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans. J Neurosurg 92 (2000) 599-605
77. Kraemer D.F., Fortin D., Doolittle N.D., and Neuwelt E.A. Association of total dose intensity of chemotherapy in primary central nervous system lymphoma (human non-acquired immunodeficiency syndrome) and survival. Neurosurgery 48 (2001) 1033-1040 discussion 1040-1041
78. Kroll R.A., and Neuwelt E.A. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 42 (1998) 1083-1099
79. Marchi N., Angelov L., Masaryk T., et al. Seizure-promoting effect of blood-brain barrier disruption. Epilepsia 48 (2007) 732-742
80. van Vliet E.A., da Costa Araújo S., Redeker S., van Schaik R., Aronica E., and Gorter J.A. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain 130 (2007) 521-534
81. Bakhshi S., and North R.B. Implantable pumps for drug delivery to the brain. J Neurooncol 26 (1995) 133-139
82. Pardridge W.M. Drug delivery to the brain. J Cereb Blood Flow Metab 17 (1997) 713-731
83. Brightman M.M., and Kaya M. Permeable endothelium and the interstitial space of brain. Cell Mol Neurobiol 20 (2000) 111-130
84. Tao A., Tao L., and Nicholson C. Cell cavities increase tortuosity in brain extracellular space. J Theor Biol 234 (2005) 525-536
85. Pardridge W.M. Transport of small molecules through the blood-brain barrier: biology and methodology. Adv Drug Deliv Rev 15 (1995) 5-36
86. Aird R.B. A study of intrathecal, cerebrospinal fluid-to-brain exchange. Exp Neurol 86 (1984) 342-358
87. Billiau A., Heremans H., Ververken D., Van Damme J., Carton H., and De Somer P. Tissue distribution of human interferons after exogenous administration in rabbits, monkeys, and mice. Arch Virol 68 (1981) 19-25
88. Covell D.G., Narang P.K., and Poplack D.G. Kinetic model for disposition of 6-mercaptopurine in monkey plasma and cerebrospinal fluid. Am J Physiol Regul Integr Comp Physiol 17 (1985) R147-R156
89. Serralta A., Barcia J.A., Ortiz P., Durán C., Hernández M.E., and Alós M. Effect of intracerebroventricular continuous infusion of valproic acid versus single i.p. and i.c.v. injections in the amygdala kindling epilepsy model. Epilepsy Res 70 (2006) 15-26
90. Boogerd W., van den Bent M.J., Koehler P.J., et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer 40 (2004) 2726-2733
91. Sandberg D.I., Bilsky M.H., Souweidane M.M., Bzdil J., and Gutin P.H. Ommaya reservoirs for the treatment of leptomeningeal metastases. Neurosurgery 47 (2000) 49-54
92. Oommen J., Kraus A., and Fisher R. Intraventricular administration of gabapentin in the rat increases flurothyl seizure threshold. Neurosci Lett 417 (2007) 308-311
93. Yildirim M., and Marangoz C. Anticonvulsant effects of focal and intracerebroventricular adenosine on penicillin-induced epileptiform activity in rats. Brain Res 1127 (2007) 193-200
94. Saltzman W.M., and Olbricht W.L. Building drug delivery into tissue engineering. Nat Rev Drug Discov 1 (2002) 177-187
95. Fung L.K., Ewend M.G., Sills A., et al. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res 58 (1998) 672-684
96. Fung L.K., Shin M., Tyler B., Brem H., and Saltzman W.M. Chemotherapeutic drugs released from polymers: distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat brain. Pharm Res 13 (1996) 671-682
97. Sawyer A.J., Piepmeier J.M., and Saltzman W.M. New methods for direct delivery of chemotherapy for treating brain tumors. Yale J Biol Med 79 (2006) 141-152
98. Kokaia M., Aebischer P., Elmér E., et al. Seizure suppression in kindling epilepsy by intracerebral implants of GABA-but not by noradrenaline-releasing polymer matrices. Exp Brain Res 100 (1994) 385-394
99. Kubek M.J., Liang D., Byrd K.E., and Domb A.J. Prolonged seizure suppression by a single implantable polymeric-TRH microdisk preparation. Brain Res 809 (1998) 189-197
100. Tamargo R.J., Rossell L.A., Kossoff E.H., Tyler B.M., Ewend M.G., and Aryanpur J.J. The intracerebral administration of phenytoin using controlled-release polymers reduces experimental seizures in rats. Epilepsy Res 48 (2002) 145-155
101. Saltzman W.M., and Langer R. Transport rates of proteins in porous materials with known microgeometry. Biophys J 55 (1989) 163-171
102. Lopez T., Ortiz E., Quintana P., and Gonzalez R.D. A nanostructured titania bioceramic implantable device capable of drug delivery to the temporal lobe of the brain. Colloids Surf A Physicochem Eng Asp 300 (2007) 3-10
103. Lopez T., Quintana P., Ascencio J., and Gonzalez R.D. The determination of dielectric constants of mixtures used in the treatment of epilepsy and the encapsulation of phenytoin in a titania matrix. Colloids Surf A Physicochem Eng Asp 300 (2007) 99-105
104. Tolmacheva E.A., and Van Luijtelaar G. Absence seizures are reduced by the enhancement of GABA-ergic inhibition in the hippocampus in WAG/Rij rats. Neurosci Lett 416 (2007) 17-21
105. Mirnajafi-Zadeh J., Mortazavi M., Fathollahi Y., Alasvand Zarasvand M., and Reza Palizvan M. Effect of transient hippocampal inhibition on amygdaloid kindled seizures and amygdaloid kindling rate. Brain Res 954 (2002) 220-226
106. Anschel D.J., Ortega E.L., Kraus A.C., and Fisher R.S. Focally injected adenosine prevents seizures in the rat. Exp Neurol 190 (2004) 544-547
107. Rossetti F., Rodrigues M.C.A., de Oliveira J.A.C., and Garcia-Cairasco N. EEG wavelet analyses of the striatum-substantia nigra pars reticulata-superior colliculus circuitry: audiogenic seizures and anticonvulsant drug administration in Wistar audiogenic rats (War strain). Epilepsy Res 72 (2006) 192-208
108. Gasior M., White N.A., and Rogawski M.A. Prolonged attenuation of amygdala-kindled seizure measures in rats by convection-enhanced delivery of the N-type calcium channel antagonists ω-conotoxin GVIA and ω-conotoxin MVIIA. J Pharmacol Exp Ther 323 (2007) 458-468
109. Morrison P.F., Chen M.Y., Chadwick R.S., Lonser R.R., and Oldfield E.H. Focal delivery during direct infusion to brain: role of flow rate, catheter diameter, and tissue mechanics [Erratum in: Am J Physiol Regul Integr Comp Physiol 2002;282(6):section R following table of contents]. Am J Physiol Regul Integr Comp Physiol 277 (1999) R1218-R1229
110. Chen M.Y., Hoffer A., Morrison P.F., et al. Surface properties, more than size, limiting convective distribution of virus-sized particles and viruses in the central nervous system. J Neurosurg 103 (2005) 311-319
111. Chen M.Y., Lonser R.R., Morrison P.F., Governale L.S., and Oldfield E.H. Variables affecting convection-enhanced delivery to the striatum: a systemic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J Neurosurg 90 (1999) 315-320
112. Raghavan R., Brady M., Rodriguez-Ponce M., Hartlep A., Pedain C., and Sampson J. Convection-enhanced delivery of therapeutics for brain disease and its optimization. Neurosurg Focus 20 4 (2006) E12
113. Neeves K.B., Lo C.T., Foley C.P., Saltzman W.M., and Olbricht W.L. Fabrication and characterization of microfluidic probes for convection enhanced drug delivery. J Control Release 111 (2006) 252-262
114. Heiss J.D., Walbridge S., Morrison P., et al. Local distribution and toxicity of prolonged hippocampal infusion of muscimol. J Neurosurg 103 (2005) 1035-1045
115. Zara G.P., Cavalli R., Bargoni A., Fundarò A., Vighetto D., and Gasco M.R. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J Drug Target 10 (2002) 327-335
116. Yan Q., Matheson C., Sun J., Radeke M.J., Feinstein S.C., and Miller J.A. Distribution of intracerebral ventricularly administered neurotrophins in rat brain and its correlation with Trk receptor expression. Exp Neurol 127 (1994) 23-36